Cardiology - Per Tornvall
The focus of the research group is general cardiology including atrial fibrillation, heart failure and ischemic heart disease. The overall aim of the research is to improve quality-of-life and prognosis, and to minimize risks of interventions for large patient groups by clinical, epidemiological and interventional studies.
Research group leader
Collaborators include other institutions at Karolinska Institutet, Uppsala University and SciLife Laboratory.
There are three main projects including studies of (1) the risk of electric cardioversion with or without anti-coagulation, including new oral anti-coagulants, (2) the risk of sotalol to maintain sinus rhythm and (3) the influence of atrial fibrillation on blood pressure. The studies are mainly observational.
The main focus is on takotsubo syndrome with studies of (1) heritability of takotsubo including genome-wide association studies, (2) diagnostic studies including cardiac magnetic resonance imaging and echocardiography and (3) treatment of stress and anxiety with internet-based interventions (randomized). There is also a mechanistic study on iron deficiency in heart failure, mainly with preserved ejection fraction.
Ischemic heart disease
Research cover four main areas and include studies of (1) the values of oxygen during admission for myocardial infarction and beta-blockers after myocardial infarction with preserved ejection fraction, (2) diagnostic algorithms for patients with chest-pain and the importance of socioeconomy, family history and other risk factors, from the emergency room to diagnosis with myocardial infarction, during secondary prevention to incident cardiovascular disease during long term follow-up, (3) the effects of new anti-diabetic treatments on coronary healing and restenosis after PCI, and (4) the assessment of the risk-benefit relationship between bleeding and ischemia in patients including a randomized trial evaluating Helicobacter Pylori screening to prevent upper gastrointestinal bleeding in patients with acute myocardial infarction. The studies are observational and randomized.
Swedish Heart and Lung Foundation
Patient organization Heart and Lung
Association between β-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry
Mars K, Wallert J, Held C, Humphries S, Ronnie Pingel, Jernberg T, et al
European heart journal Acute cardiovascular care 2020
Effect of Oxygen Therapy on Cardiovascular Outcomes in Relation to Baseline Oxygen Saturation.
James SK, Erlinge D, Herlitz J, Alfredsson J, Koul S, Fröbert O, et al
JACC. Cardiovascular interventions 2020;13(4):502-513
Elevated Blood Pressure in the Emergency Department: A Risk Factor for Incident Cardiovascular Disease.
Oras P, Häbel H, Skoglund PH, Svensson P
HYPERTENSION 2020 01;75(1):229-236
Abdominal obesity and the risk of recurrent atherosclerotic cardiovascular disease after myocardial infarction.
Mohammadi H, Ohm J, Discacciati A, Sundstrom J, Hambraeus K, Jernberg T, et al
European journal of preventive cardiology 2020 Jan;():2047487319898019
Designing a Web-Based Psychological Intervention for Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: User-Centered Design Approach.
Humphries SM, Rondung E, Norlund F, Sundin Ö, Tornvall P, Held C, et al
J Med Internet Res. 2020 Sep;22(9):e19066
Self-rated stress and experience in patients with Takotsubo syndrome: a mixed methods study.
Sundelin R, Bergsten C, Tornvall P, Lyngå P
Eur J Cardiovasc Nurs. 2020 Jun;():1474515120919387
Increased iron absorption in patients with chronic heart failure and iron deficiency.
Cabrera CC, Ekström M, Linde C, Persson H, Hage C, Eriksson MJ, et al
J Card Fail. 2020 May;26(5):440-443